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OBJECTIVE—Genome-wide association studies have identiﬁed
a single nucleotide polymorphism (SNP), rs560887, located in a
G6PC2 intron that is highly correlated with variations in fasting
plasma glucose (FPG). G6PC2 encodes an islet-speciﬁc glucose-
6-phosphatase catalytic subunit. This study examines the contri-
bution of two G6PC2 promoter SNPs, rs13431652 and rs573225,
to the association signal.
RESEARCH DESIGN AND METHODS—We genotyped 9,532
normal FPG participants (FPG 6.1 mmol/l) for three G6PC2
SNPs, rs13431652 (distal promoter), rs573225 (proximal pro-
moter), rs560887 (3rd intron). We used regression analyses
adjusted for age, sex, and BMI to assess the association with FPG
and haplotype analyses to assess comparative SNP contribu-
tions. Fusion gene and gel retardation analyses characterized the
effect of rs13431652 and rs573225 on G6PC2 promoter activity
and transcription factor binding.
RESULTS—Genetic analyses provide evidence for a strong
contribution of the promoter SNPs to FPG variability at the
G6PC2 locus (rs13431652: 0.075, P  3.6  10
35; rs573225
0.073 P  3.6  10
34), in addition to rs560887 (0.071,
P  1.2  10
31). The rs13431652-A and rs573225-A alleles
promote increased NF-Y and Foxa2 binding, respectively. The
rs13431652-A allele is associated with increased FPG and ele-
vated promoter activity, consistent with the function of G6PC2 in
pancreatic islets. In contrast, the rs573225-A allele is associated
with elevated FPG but reduced promoter activity.
CONCLUSIONS—Genetic and in situ functional data support a
potential role for rs13431652, but not rs573225, as a causative
SNP linking G6PC2 to variations in FPG, though a causative role
for rs573225 in vivo cannot be ruled out. Diabetes 59:2662–
2671, 2010
T
he glucose-6-phosphatase catalytic subunit gene
family comprises three members, G6PC, G6PC2,
and G6PC3 (1). G6PC2, also known as the IGRP
gene (2–4), is principally expressed in the -cells
of pancreatic islets (5). Whether G6PC2 accounts for the
low glucose-6-phosphatase enzyme activity detected in
islets is unclear (2,3,6,7); however, a global knockout of
G6pc2 results in a mild metabolic phenotype characterized
by a 15% decrease in fasting blood glucose (4). This
observation suggests that G6PC2 may oppose the action of
glucokinase and therefore modulate -cell glycolytic ﬂux
and glucose-stimulated insulin secretion (8). This hypoth-
esis is consistent with recent genetic studies in humans.
Thus, using a genome-wide association approach to study
the genetic basis for variations in fasting plasma glucose
levels (FPG), we recently identiﬁed strong association
signals in and around G6PC2 (9). FPG is an important
metabolic trait that is correlated with cardiovascular-
associated mortality (10,11). We showed that rs560887, a
common variant located in the 3rd intron of G6PC2, may
explain 1% of the total variance in FPG. The rs560887-A
allele is associated not only with elevated FPG, but also
with long-term glucose regulation, as estimated by ele-
vated glycated hemoglobin A1C levels, decreased basal
insulin secretion, as assessed by Homa%B, and increased
risk of incidence of impaired fasting glucose over time
using prospective data from the DESIR study (9). Data
from an independent study reported similar ﬁndings (12),
and another meta-analysis conﬁrmed that the G6PC2 locus
harbors the strongest genetic determinant of FPG in terms
of effect size and signiﬁcance (13). However, a functional
link between the genetic variation in the G6PC2 locus and
variations in FPG remains to be determined.
Two genetic variants located in the G6PC2 promoter
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variants (MAF 0.05) that show high LD (0.80) with
rs560087, according to HapMap phase III data (r
2  0.88
and r
2  0.96, respectively), but their precise correlation
with rs560887 and their contribution to the association
with FPG in large and independent samples have not been
investigated. In this report, we provide genetic support for
the contribution of rs13431652 and rs573225 to the asso-
ciation signal between G6PC2 and FPG, but we do not
exclude a role for rs560887. We also characterize the effect
of these two G6PC2 promoter variants on transcription
factor binding and G6PC2 fusion gene expression. We
show that the rs13431652-A allele affects binding of the
transcription factor NF-Y and that it is associated with
both elevated FPG and elevated fusion gene expression, a
correlation that is consistent with the function of G6PC2
(4) since elevated G6PC2 expression would oppose the
action of glucokinase leading to elevated FPG. In contrast,
we show that the rs573225-A allele affects binding of the
transcription factor Foxa2 and that it is associated with
elevated FPG but reduced fusion gene expression. These
functional data support a potential role for rs13431652, but
not rs573225, as a causative single nucleotide polymor-
phism (SNP) linking G6PC2 to variations in FPG.
RESEARCH DESIGN AND METHODS
Study participants. We analyzed 9,532 normal fasting glucose (NG) Euro-
peans drawn from three general population studies (DESIR, N  3,483; NFBC
1986, N  4,372; and the Haguenau Study, N  1,201) and one childhood
obesity case population (N  476).
DESIR. The data from the Epidemiological Study on the Insulin Resistance
Syndrome (DESIR) cohort is a longitudinal French general population cohort
that is fully described elsewhere (9,14). Because ethnicity could not be legally
documented in the DESIR study, the proportion of subjects having non-
European ancestry was estimated to be low (0.30%) (15). We also excluded
all individuals born outside metropolitan France before analysis. We analyzed
3,483 normoglycemic (NG) DESIR participants successfully genotyped for all
SNPs with fasting plasma glucose (FPG) available (supplementary Table 1
available in an online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0389/DC1). The study protocol was approved by the Ethics
Committee of Bice ˆtre Hospital (Paris, France).
NFBC 1986. The Northern Finland 1986 Birth Cohort (NFBC 1986) is a
prospective 1-year birth cohort including all white Caucasian mothers with
children whose expected dates of birth fell between July 1, 1985, and June 30,
1986, in the two northernmost provinces of Finland (16). The clinical
examinations were conducted between August 2001 and June 2002. All cohort
members living in Finland with known addresses were invited, and 6,798
(74%) participated. Overall, we analyzed 4,372 NG individuals of the NFBC
1986 cohort successfully genotyped for all SNPs with FPG available (supple-
mentary Table 1). The study protocol was approved by the Ethics Committee
of the Faculty of Medecine of the University of Oulu, Finland and the Finnish
Ministry of Social and Health Affairs.
Obese children. NG obese French children with European ancestry were
selected from obesity nuclear families recruited by the CNRS-UMR8090 unit
(Lille, France) through an ongoing national media campaign (17). We analyzed
476 NG unrelated obese children (deﬁned as BMI 97th percentile for age and
sex according to a French population-based cohort) (18) who were success-
fully genotyped for all SNPs with FPG available (supplementary Table 1).
Haguenau. The Haguenau population is a community-based cohort of young
adults that investigates the long-term consequences of being born small for
gestational age and was fully described elsewhere (19). Brieﬂy, subjects born
between 1971 and 1985 were identiﬁed from a population-based registry of
Haguenau, France. Non-European ancestry subjects are estimated to be
0.1% of the general population (19). At a mean age of 22 years, participants
underwent a medical examination to assess anthropometric and clinical
parameters. We analyzed 1,201 NG subjects successfully genotyped for all
SNPs with FPG available (supplementary Table 1). The study protocol was
approved by the Ethics Committee of Paris St. Louis University (Paris,
France).
All study participants and parents of children signed an informed consent
form. For each population, glycemic status was deﬁned according to the 1997
American Diabetes Association criteria (20): normal glucose, deﬁned as FPG
6.1 mmol/l without hypoglycemic treatment; impaired fasting glucose,
deﬁned as FPG between 6.1 and 6.99 mmol/l without hypoglycemic treatment;
and type 2 diabetes, deﬁned as FPG 7.0 mmol/l and/or treatment with
antidiabetic agents.
Genotyping. Genotyping was performed using either TaqMan assays or
SNPlex technology (Applied Biosystems) according to the manufacturer’s
instructions. The genotyping success rate was at least 95% and genotype
concordance between the two methods is more than 99% (internal data). No
signiﬁcant deviation (P  0.05) from the Hardy-Weinberg equilibrium was
observed. To allow optimal analytical conditions, all individuals in this study
were successfully genotyped for the four SNPs studied here.
Genotype/expression correlation in human pancreatic cDNAs. Please
see the online appendix (available at http://diabetes.diabetesjournals.org/
cgi/content/full/db10-0389/DC1).
G6PC2 expression pattern in human tissues. We used commercial cDNAs
from the Human Multiple Tissue cDNA Panel I for lung, liver, heart, skeletal
muscle, kidney, placenta, and pancreas (BD Biosciences Clontech), and RNAs
that were reverse-transcribed from the brain, small intestine, and adipose
tissue (Human Adult Normal 5 Donor Pool, BioChain Institute). Pancreatic
islets and sorted -cells were obtained from human adult brain-dead donors in
accordance with French regulations and the local institutional ethical com-
mittee, as previously described (21). Brieﬂy, pancreatic islets were isolated
after ductal distension of the pancreata and digestion of the tissue with
Liberase (Roche Diagnostics). Human -cells were sorted by ﬂuorescence-
activated cell sorter (FACS) analysis of semipuriﬁed preparations of islet cells
using Newport Green, a zinc-speciﬁc ﬂuorescent probe (21). Total RNA was
extracted using a Nucleospin RNA II kit (Macherey Nagel) according to the
manufacturer’s instructions. Samples were treated with DNase I (Ambion) to
ensure that residual genomic contamination was removed. For each sample, 1
g of total RNA was used to generate cDNA by random, primed, ﬁrst-strand
synthesis (Applied Biosystems) according to manufacturer’s protocol. Result-
ing cDNAs were diluted 10-fold, and 4 l of each sample was used in a 20-l
quantitative RT-PCR reaction including 10 l of TaqMan gene expression
mastermix (Applied Biosystems) and 1 l of the appropriate TaqMan gene
expression assay (Applied Biosystems). Quantitative RT-PCR analyses were
performed with the ABI 7900 HT SDS 2.3 software, and each sample was run
in triplicate. G6PC2 (assay-on-demand ID: Hs01549773_m1, sequence context:
ACAGGTCCAGGAAGTCCATCTGGCC) expression levels were obtained rela-
tive to the POLR2A housekeeping gene (ID: Hs00172187_m1, sequence
context: CGGATGAACTGAAGCGAATGTCTGT). Content of cDNA samples
was normalized by subtracting the number of copies of the mean of the
housekeeping gene from the number of copies of the target gene (	Ct  Ct of
target gene – Ct of housekeeping gene). Expression of the speciﬁc gene was
calculated using the formula 100  2-	Ct.
Fusion gene plasmid construction. The construction of mouse G6pc2-
chloramphenicol acetyltransferase (CAT) fusion genes containing the wild-
type promoter sequence from 306 to 
3, or the same sequence with a
site-directed mutation (SDM) of the Foxa2 binding site have been previously
described (22,23). The construction of a human G6PC2-CAT fusion gene
containing the wild-type promoter sequence from 324 to 
3 has also been
previously described (3). A three-step PCR strategy (24) was used to introduce
the rs573225-G allele (Fig. 4A) or a two base pair mutation (supplementary
Table 6) into the Foxa2 binding site in the human G6PC2 promoter within the
context of the 324 to 
3 promoter fragment. All promoter fragments were
subcloned into the pGL3 MOD and/or pGL4 MOD luciferase expression
vectors (25). pGL3 MOD and pGL4 MOD were generated by replacing the
polylinker in the pGL3-Basic or pGL4.16 vectors (Promega) with a polylinker
containing the following restriction endonuclease recognition sites: KpnI,
BamHI, HindIII, XbaI, XhoI, and BglII.
A 8,574 base pair Mfe I DNA restriction fragment extending from 8,563 to

11 relative to the human G6PC2 gene transcription start site was isolated from
the previously described Pac 294 clone (3). This Mfe I DNA fragment was ligated
into the EcoRI site of the pGEM7 vector (Promega) and the resulting plasmid was
designated G6PC2Pac294MfepGEM7. The alleles of rs573225 and rs13431652
present within the Pac 294 derived 8,563 to 
11 G6PC2 promoter fragment
were determined through DNA sequencing. Two additional G6PC2 subclones
were then generated in pGEM7 so as to change the sequences of rs573225 and
rs13431652 to their alternative alleles by site-directed mutagenesis. One of these
subclones, designated G6PC2Pac294SacShuttlepGEM7, was generated by isolat-
ing a SacI fragment from G6PC2Pac294MfepGEM7 that contained human G6PC2
promoter sequence from 8,563 to 4,390. The second subclone, designated
G6PC2Pac294XmaShuttlepGEM7, was generated by isolating an XmaI fragment
from G6PC2Pac294MfepGEM7 that contained human G6PC2 promoter sequence
from 2,803 to 
11. The G6PC2Pac294SacShuttlepGEM7 plasmid was used
as a template along with mutagenesis primers 5-TGTCAGGCAGGCTG
TGTCACTGGAGGGAAG-3 and 5-CTTCCCTCCAGTGACACAGCCTGCCT
GACA-3 to convert rs13431652 at position 4,405 from T to C and the
N. BOUATIA-NAJI AND ASSOCIATES
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mutagenesis primers 5-GGAAATGAACTGTACAAAAAATTTCAAGCAAA
CATGATCCAACTGTTC-3 and 5-GAACAGTTGGATCATGTTTGCTTGAA
ATTTTTTGTACAGTTCATTTCC-3 to convert rs573225 at position 259
from A to G. Mutagenesis was performed with these templates and primers
using a QuikChange II Kit (Stratagene) as described by the manufacturer.
G6PC2-luciferase reporter plasmids, containing promoter sequence from
8,563 to 
11, were generated in the pGL3-Basic and pGL4.16 vectors
(Promega) by a two-step process. In the initial cloning step, a SacI-HinD III
fragment was isolated from the G6PC2Pac294MfepGEM7 plasmid, using a
SacI site in G6PC2 at 4,395 and a HinD III site within the pGEM7 vector, and
ligated into the SacI-HinD III digested pGL3-Basic and pGL4.16 vectors to
generate fusion gene constructs that contain G6PC2 promoter sequence from
4,395 to 
11. In the second cloning step a SacI fragment was isolated from
the G6PC2Pac294SacShuttlepGEM7 plasmid and ligated into the SacI digested
4,395 pGL3-Basic and pGL4.16 fusion gene plasmids to extend the G6PC2
promoter sequences from 4,395 to 8,563.
A SacI fragment from the G6PC2Pac294SacShuttlepGEM7 plasmid con-
taining the alternate rs13431652 allele and an XmaI fragment from the
G6PC2Pac294XmaShuttlepGEM7 plasmid with the alternate rs573225 allele
were then exchanged with the corresponding SacI and/or XmaI fragments that
contain the original Pac294 sequences to generate pGL3-Basic and pGL4.16
plasmids with the alternate SNP alleles within the context of the G6PC2
promoter region from 8,563 to 
11.
Cell culture, transient transfection and luciferase assays. Hamster
insulinoma tumor (HIT), TC-3, and Min6 cells were cultured and transfected
using lipofectamine as previously described (23). Luciferase assays were
performed as previously described (23).
Gel retardation assays
Labeled probes. Sense and anti-sense oligonucleotides representing wild-
type or mutant Foxa binding sites (supplementary Table 6) or the rs573225
variants (Fig. 4A) were synthesized with BamHI compatible ends. Oligonu-
cleotides representing the rs13431652 variants of the NF-Y binding site (Fig.
1A) were synthesized with HinDIII compatible ends. Oligonucleotides were
subsequently gel puriﬁed, annealed, and labeled with [
32P]dATP using the
Klenow fragment of Escherichia coli DNA Polymerase I to a speciﬁc activity
of 2.5 Ci/pmol (26).
Nuclear extract preparation. The preparation of TC-3 and H4IIE nuclear
extracts through extraction of nuclei with 800 mmol/l NaCl (designated high
salt) was as previously described (24). The preparation of rat liver nuclear
extract was also performed as previously described (27).
Binding assays. Approximately 14 fmol of radiolabeled probe (50,000
cpm) was incubated with the indicated nuclear extract in a ﬁnal 20 l reaction
volume. Foxa2 binding reactions contained 1.0 g TC-3, 2.0 g liver, or 2.0
g H4IIE nuclear extract, 20 mmol/l Hepes pH 7.9, 0.1 mmol/l EDTA, 0.1
mmol/l EGTA, 10% glycerol (v/v), 1 mmol/l dithiothreitol, 1 g poly(dI-
dC)poly(dI-dC), and 100 mmol/l KCl. NF-Y binding reactions contained 2.0 g
high salt TC-3 nuclear extract, 20 mmol/l Hepes pH 7.9, 0.1 mmol/l EDTA, 0.1
mmol/l EGTA, 10% glycerol (v/v), 1 mmol/l dithiothreitol, 1 g poly(dI-
dC)poly(dI-dC), and 50 mmol/l KCl. After incubation at room temperature for
20 min, samples were loaded onto a 6% polyacrylamide gel containing 1X TGE
(25 mmol/l Tris Base, 190 mmol/l glycine, 1 mmol/l EDTA) and 2.5% (v/v)
glycerol. Samples were electrophoresed for 1.5 h at 150V in 1X TGE buffer
before the gel was dried and then exposed to Kodak XB ﬁlm with intensifying
screens. Competition and supershift experiments were performed as previ-
ously described (24). For supershift experiments, antisera raised against
Foxa2 (HNF-3) (sc-65540x) and NF-Y (sc-17753x) were obtained from Santa
Cruz Biotechnology.
Statistical analysis. The effect of SNPs on FPG was analyzed using linear
regression models under the additive model adjusted for age, sex, and BMI.
The estimates of the effect of each SNP on FPG and their standard errors for
each separate population were combined in the meta-analysis using the
weighted inverse normal method. The overall effect and its CI were estimated
using the inverse variance method implemented using the meta.summaries
function of the R meta package. No heterogeneity in effects was observed
(P  0.44). All statistical analyses of genetic data were performed with R
(version 2.6.1), combined with the survival and rmeta packages. Please see the
online supplementary appendix for haplotype analyses.
To test the effect of a speciﬁc SNP in comparison with the effects of other
SNPs inside a 2  2 haplotype, we analyzed haplotype genetic models using
the THESIAS program (28) in each population separately. This method
estimates the likelihood of speciﬁed models for haplotype effects under the
general linear model (GLM) framework, and allows testing of constrained
models. This analysis aimed at testing 2-SNP models while accounting for the
high correlation between SNPs (unlike a plain 2-loci regression model). The
model M1 is a 2-SNP (labeled SNP1 and SNP2) model with each haplotype
effect being allowed to vary, and 1 and 2 being the at-risk (increasing) alleles
of each SNP. The model Mno1 is a model in which the effect of the ﬁrst SNP
is null, or, translated in haplotype model language, 1–1  2–1 and 1–2 
2–2. Conversely, Mno2 is a model in which 1–1  1–2 and 2–1  2–2. A
signiﬁcant difference between M1 and Mno2 would mean that we could not
ignore the effect of SNP2 (supplementary Table 3).
The transfection data were analyzed for differences from the control
values, as speciﬁed in the ﬁgure legends. Statistical comparisons were
calculated using an unpaired Student t test. The level of signiﬁcance was P 
0.05 (two-sided test).
RESULTS
G6PC2 promoter variants strongly associate with
FPG. Only two common SNPs (minor allele frequency
0.05), namely rs13431652 and rs573225, are reported to
be in high linkage disequilibrium (LD) with the previously
identiﬁed intronic G6PC2 SNP rs560887 (r
20.80, accord-
ing to HapMap data [release XX]). rs13431652 is located in
the distal G6PC2 promoter, at 4,405 relative to the
transcription start site, whereas rs573225 is located in the
proximal promoter at 259. We have assessed the effect of
these two G6PC2 promoter variants on FPG, adjusted for
age, sex and BMI in 9,532 NG Europeans from four
independent populations. In the meta-analyses, we show
strong associations of both rs13431652 (0.075, P 
3.6  10
35) and rs573225 (0.073, P  3.6  10
34)
with FPG, in similar magnitude to that for rs560887 (
0.071, P  1.2  10
31) (Table 1). Conditioned regression
model analyses to assess the independency of the three
SNPs studied turn out to be noninformative (data not
shown), as these analyses include a high variance inﬂation
factor because of high LD that we observed between the
SNPs in our populations (supplementary Table 2).
To compensate for this limited analytical situation, we
analyzed the association of FPG with multiple haplotypes
of the promoter variants and rs560887, speciﬁcally individ-
ual contributions of each variant and contributions when
variants were analyzed in pairs and when we constrained
the effect of rs560887 to be null (see supplementary
METHODS). Because of the LD discrepancies between pop-
ulations (supplementary Table 2), these haplotype analy-
ses were conducted in the four populations separately
(supplementary Table 3). In DESIR, we found that
rs560887 is signiﬁcantly contributing to the haplotype
association in combination with rs13431652 (P  7.58 
10
5) and rs573225 (P  0.015). We also observed a
signiﬁcant contribution of rs13431652 (P  4.09  10
7)
and rs573225 (P  1.21  10
8) to the haplotype associa-
tions, supporting independent effects of both promoter
variants to the global association of the haplotype in
combination with rs560887. In contrast, distinct results
were obtained in the remaining cohorts in which we found
that both promoter and intronic variants are not indepen-
dently contributing to the haplotype associations, suggest-
ing that promoter and intronic variants are indispensable
to the two by two haplotype associations, with a modestly
more signiﬁcant contribution of rs560887 (P  0.006
against rs13431652 and P  0.07 against rs573225) in the
NFBC 1986 cohort (supplementary Table 3). We speculate
that these distinct results in some way reﬂect the differ-
ences in LD within the different cohorts. Despite these
differences, haplotype analyses support a substantial role
of promoter variants to the association signal with FPG,
and do not discard the contribution of rs560887.
We have also assessed the effect of the intronic variant
rs853789 located in the 19th intron of ABCB11, one of two
SNPs, along with rs560887, that were reported by Chen et
al. (12) to be associated with FPG. ABCB11 (ATP-binding
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pump and is expressed predominantly in the liver (29) and
was hypothesized to potentially drive the association with
FPG observed at this locus (12). We found a signiﬁcant
association between rs853789 and FPG ( 0.062, P 
1.1  10
25, supplementary Table 4). However, when we
include either rs560887, rs13431652, or rs573225 in a
regression conditional model that includes rs853789, age,
sex, BMI, and cohort, the effect of rs853789 is highly
reduced (supplementary Table 4), whereas rs13431652
(P  1.2  10
10), rs573225 (P  1.8  10
9), and rs560887
(P  1.3  10
7) remain strongly associated with FPG
(supplementary Table 5). These ﬁndings were conﬁrmed
by the haplotype analyses that did not support a frank,
independent contribution of rs853789 to the association in
any of the cohorts studied (supplementary Table 3). These
genetic data suggest that in our populations, the ABCB11
rs853789 effect on FPG is driven mainly by G6PC2 varia-
tion through moderate LD, estimated between 0.42 and
0.78, depending on the population studied (supplementary
Table 5).
Expression analyses. Using quantitative real time PCR
we conﬁrmed that the expression of G6PC2 is restricted to
pancreatic tissues, including whole pancreas, islets and
sorted -cells, in humans (supplementary Fig. 1A). Similar
results were previously reported through RNA blotting
analyses of mouse (2,9) and human (3) RNA. In a limited
sample (N  24) in which pancreatic islet cDNAs and
corresponding genomic DNAs were available, we found no
signiﬁcant correlation between the alleles of rs13431652-A,
rs573225-A, or rs560887-G, that are associated with high
FPG and G6PC2 gene expression (supplementary Fig. 1B).
Because of the limited sample sizes in the genetic and
expression analyses, it was not possible to identify a
causative variant among rs13431652, rs573225, and
rs560887. We therefore decided to take a biochemical
approach to assess the ability of the promoter variants to
affect transcription factor binding and G6PC2 promoter
activity and, hence, their ability to alter FPG levels.
NF-Y binds to the G6PC2 promoter in vitro. The
G6PC2 promoter region that encompasses rs13431652 was
analyzed using MatInspector sequence analysis software
(30) with the goal of identifying a cis-acting element
whose binding of its cognate trans-acting factor was likely
to be affected by the alternate rs13431652 alleles. This
analysis identiﬁed a CCAAT box (Fig. 1A), an element
known to bind multiple transcription factors, including
NF-Y (31,32). The SNP changes the sequence CCAaT to
CCAgT.
Gel retardation assays were used to investigate whether
NF-Y can bind to this G6PC2 promoter region in vitro.
When a labeled double-stranded oligonucleotide, desig-
nated rs13431652-A, representing the G6PC2 promoter
sequence from 4,425 to 4,392 and the rs13431652-A
allele (Fig. 1A), was incubated with nuclear extract pre-
pared from TC-3 cells a single protein-DNA complex was
detected (Fig. 1B).
To identify the factor present in this complex, a gel
retardation assay was performed in which TC-3 cell
nuclear extract was preincubated with antisera speciﬁc for
NF-Y or, as a control, USF-2. As can be seen in Fig. 1B,
addition of antibodies recognizing NF-Y resulted in a clear
supershift in the migration of the complex, whereas the
addition of antibodies recognizing USF-2 had no effect.
This result strongly suggests that the complex represents
NF-Y binding.
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varying molar excess of unlabeled DNA was included with
the labeled rs13431652-A oligonucleotide, were used to
compare the afﬁnity of NF-Y binding to the rs13431652
variants of the G6PC2 NF-Y binding site. Fig. 2A shows
that the rs13431652-A oligonucleotide competed more
effectively than the rs13431652-G oligonucleotide for the
formation of the NF-Y-DNA complex and quantitation of
the results of several experiments (Fig. 2B) showed that
NF-Y binds the rs13431652-A oligonucleotide with approx-
imately ﬁvefold higher afﬁnity. Interestingly, in contrast to
the competition experiment data (Fig. 2B), the direct
analysis of NF-Y binding to the rs13431652-A and -G
oligonucleotide probes, labeled with the identical speciﬁc
activity, suggested a much more dramatic difference in
NF-Y binding afﬁnity to the rs13431652-A and -G oligonu-
cleotides (Fig. 2C). We recently reported a similar discrep-
ancy between the results of gel retardation competition
and binding experiments in studies on FOXO1 binding
(33). We hypothesize that such apparent discrepancies can
arise when both the association and dissociation rate of
factor binding to DNA are simultaneously increased since
this would result in limited change in KD (34), but a
marked difference in the dissociation of the protein-DNA
complex upon separation of bound and free probe during
electrophoresis.
rs13431652 alters G6PC2 fusion gene expression. We
next investigated the functional signiﬁcance of altered
NF-Y binding on human G6PC2 promoter activity. NF-Y
can function as either an activator or repressor such that
the effect of NF-Y on gene transcription is context depen-
dent (35). Fusion genes containing each of the rs13431652
alleles, generated in the context of the 8,563 to 
11
G6PC2 promoter region, were analyzed by transient trans-
fection of TC-3 cells. Fig. 3 shows that the rs13431652-G
allele was associated with an 25% decrease in promoter
activity in comparison with that observed with the
rs13431652-A allele. Supplementary Fig. 2 shows that this
difference was observed only when the G6PC2 promoter
was analyzed in the context of the pGL4, but not the pGL3
vector. The former is an improved vector that lacks
multiple transcription factor binding sites in the plasmid
backbone and luciferase gene that are known to occasion-
ally give rise to spurious data (23). These results indicate
that NF-Y acts as an activator in the context of the G6PC2
promoter. More importantly, these data are consistent
with the reduced FPG observed in G6pc2 knockout mice
(4) in that the rs13431652-A allele is associated with both
elevated FPG (Table 1) and G6PC2 promoter activity. As
such, these functional data support a potential role for
rs13431652 as a SNP linking G6PC2 to variations in FPG.
Foxa2 binds to the G6PC2 promoter in vitro. The
G6PC2 promoter region that encompasses rs573225 is
highly conserved in the mouse G6pc2 promoter (3). We
FIG. 1. NF-Y binds the 4,425/4,392 G6PC2 promoter region in vitro.
A: The sense strand sequences of the oligonucleotides used in gel
retardation assays are shown. SNP base pairs are shown in bold lower
case letters. The consensus NF-Y binding motif, CCAAT, is taken from
Quandt et al. (31). B: TC-3 nuclear extract was incubated in the
absence or presence of the indicated anti-serum for 10 min on ice. A
labeled oligonucleotide representing the 4,425/4,392 G6PC2 pro-
moter region and containing the rs13431652-A allele (rs13431652-A;
panel A) was then added and incubation continued for 20 min at room
temperature. Protein binding was then analyzed using the gel retarda-
tion assay as described in RESEARCH DESIGN AND METHODS.I nt h e
representative audioradiograph shown, only the retarded complexes
are visible and not the free probe, which was present in excess.
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FIG. 2. Comparison of the afﬁnity of NF-Y binding to the rs13431652-A
and rs13431652-G variants of the G6PC2 NF-Y binding site in vitro. A:
The labeled rs13431652-A oligonucleotide (Fig. 1A) was incubated in
the absence or presence of the indicated molar excess of the unlabeled
human rs13431652-A or rs13431652-G oligonucleotide competitors
(Fig. 1A) before the addition of TC-3 cell nuclear extract. Protein
binding was then analyzed using the gel retardation assay as described
in RESEARCH DESIGN AND METHODS. In the representative autoradiograph
that is shown, only the retarded complexes are visible and not the free
probe, which was present in excess. B: Protein binding was quantiﬁed
by using a Packard Instant Imager to count
32P associated with the
retarded complex. The data represent the mean  SEM of three
experiments. C: The labeled rs13431652-A and rs13431652-G oligonu-
cleotides (Fig. 1A) were incubated with TC-3 cell nuclear extract, and
protein binding was analyzed using the gel retardation assay as de-
scribed in RESEARCH DESIGN AND METHODS. In the representative audio-
radiograph shown, only the retarded complexes are visible and not the
free probe, which was present in excess.
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of the mouse G6pc2 promoter and showed that it contains
a Foxa2 binding site (23). In addition, we demonstrated,
using chromatin immunoprecipitation (ChIP) assays, that
Foxa2 binds the endogenous G6pc2 promoter in mouse
TC-3 cells in situ (23). Fig. 4 shows that this region of
the human G6PC2 promoter also binds Foxa2 in vitro.
When labeled double-stranded oligonucleotides, desig-
nated rs573225-A and rs573225-G (Fig. 4A), representing
the G6PC2 promoter sequence from 265 and 246 and
the rs573225-A and -G alleles, respectively, were incubated
with rat liver nuclear extract, a single major complex,
designated A2, was detected with both alleles (Fig. 4B).
When rat liver nuclear extract was preincubated with
antisera speciﬁc for Foxa2, a clear supershift in the
migration of complex A2 was observed (Fig. 4B), strongly
suggesting that this complex represents Foxa2 binding.
This experiment was performed using rat liver nuclear
extract because, like pancreatic islets (36), it contains
both Foxa1 and Foxa2 (37). In contrast, TC-3 cells
express only Foxa2 (23). The results indicate that rs573225
does not differentially affect binding of these related
factors, instead both alleles strongly bind Foxa2.
Gel retardation competition experiments, in which a
varying molar excess of unlabeled DNA was included with
the labeled rs573225-A probe, were used to compare the
afﬁnity of Foxa binding to the rs573225 variants of the
G6PC2 Foxa binding site. Fig. 5A shows that when using
rat liver nuclear extract, both the rs573225-A and
rs573225-G oligonucleotides competed equally effectively
for the formation of the Foxa2-DNA complex. Quantitation
of the results of several experiments conﬁrmed that Foxa2
binds the rs573225-A and rs573225-G oligonucleotides with
equal afﬁnity (Fig. 5B). Identical results were obtained
using mouse TC-3 cell nuclear extract (Fig. 5A). We have
previously shown that the two complexes detected using
TC-3 cell nuclear extract represent the binding of Foxa2
(A2) and an unknown factor that either represents a
nonspeciﬁc (NS) interaction or binding to another region
of the probe (23).
Interestingly, in contrast with the competition experi-
ment data (Fig. 5A and B), the direct analysis of Foxa2
binding to the rs573225-A and rs573225-G oligonucleotide
probes labeled with the identical speciﬁc activity showed
that Foxa2 binds with slightly higher afﬁnity to the
rs573225-A allele (Figs. 4B and 5C). An identical observa-
tion was made using rat liver and rat H4IIE hepatoma cell
nuclear extract (Fig. 5C). As explained above in the
analysis of NF-Y binding (Fig. 2C), this suggests that
rs573225 alters the association and dissociation rates of
Foxa2 binding without affecting binding afﬁnity.
rs573225 alters G6PC2 promoter activity in an unex-
pected direction. We next investigated the functional
signiﬁcance of altered Foxa2 binding on human G6PC2
promoter activity. A block mutation in the G6PC2 Foxa
binding site that abolishes Foxa2 binding (supplementary
Fig. 3) also markedly reduces fusion gene expression
(supplementary Fig. 4), indicating that Foxa2 is an activa-
tor in the context of the human G6PC2 promoter, as it is
in the mouse G6pc2 promoter (23). Fusion genes contain-
ing each rs573225 variant generated in the context of the
324 to 
3 (Fig. 6) and 8,563 to 
11 (Fig. 7) G6PC2
promoter regions, were analyzed by transient transfection
of TC-3 cells. Since the loss of Foxa2 binding reduces
G6PC2 promoter activity (supplementary Fig. 4), and
because the rs573225-G allele decreases Foxa2 binding
(Fig. 5C), we anticipated that the rs573225-G allele would
also be associated with reduced G6PC2 promoter activity.
Surprisingly, Figs. 6 and 7 show that the rs573225-G allele
was associated with an increase in promoter activity in
comparison with that observed with the rs573225-A allele.
This result is not explained by the de novo creation of an
activator binding site by the rs573225-G allele (Fig. 4B).
Supplementary Figs. 5 and 6 show that a similar effect of
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FIG. 3. The human G6PC2 rs13431652-G allele is associated with
decreased G6PC2 promoter activity relative to the rs13431652-A al-
lele. TC-3 cells were transiently cotransfected, as described in RE-
SEARCH DESIGN AND METHODS, using a lipofectamine solution containing
various G6PC2-luciferase fusion genes in the pGL4 MOD vector (2 g)
and an expression vector encoding Renilla luciferase (0.5 g). The
G6PC2-luciferase fusion genes represented the rs13431652-A or
rs13431652-G alleles present in the context of the human G6PC2
promoter sequence located between 8,563 and 11. After transfec-
tion, cells were incubated for 18–20 h in serum-containing medium. The
cells were then harvested, and ﬁreﬂy and Renilla luciferase activity
were assayed as described in RESEARCH DESIGN AND METHODS. Results are
presented as the ratio of ﬁreﬂy:Renilla luciferase activity, expressed
as a percentage relative to the value obtained with the rs13431652-A
allele, and represent the mean of 12 experiments  SEM, each using an
independent preparation of each fusion gene plasmid, assayed in
triplicate. *P < 0.05 vs. rs13431652-A allele.
Foxa2
Antiserum: None
Probe: rs573225-A
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B
FIG. 4. Foxa2 binds the human G6PC2 265/246 promoter region in
vitro. A: The sense strand sequences of the oligonucleotides used in gel
retardation assays are shown. SNP base pairs are shown in bold lower
case letters. The consensus Foxa binding motif, (A/G)A(G/A)(C/T)(C/
A)AA(C/T)A(T/A)T(T/G/C), is taken from Overdier et al. (46). B: Liver
nuclear extract was incubated in the absence () or presence of the
indicated anti-serum for 10 min on ice. Labeled oligonucleotides
representing the 265/246 G6PC2 promoter region and containing
the rs573225-A or rs573225-G alleles (rs573225-A or rs573225-G; panel
A) were then added and incubation continued for 20 min at room
temperature. Protein binding was then analyzed using the gel retarda-
tion assay as described in RESEARCH DESIGN AND METHODS.I nt h e
representative audioradiograph shown, only the retarded complexes
are visible and not the free probe, which was present in excess. A single
major complex was detected (A2) that represents Foxa2 binding. The
arrow indicates a supershifted complex.
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cell lines and when the G6PC2 promoter was analyzed in
the context of both the pGL4 and pGL3 vectors, respec-
tively. Since the Foxa2 binding site incorporates the target
sequence for the bacterial Dam methylase (GATC), we
repeated this analysis using plasmids grown in SCS110
Dam and Dcm methylase-deﬁcient bacteria. Supplemen-
tary Fig. 7 shows that Dam methylation of the Foxa2
binding site did not alter the stimulatory effect of rs573225
on fusion gene expression. Although the increased pro-
moter activity observed with the rs573225-G allele was
unexpected, given the reduction in Foxa2 binding, the key
observation here is that the functional data obtained with
rs573225 are not consistent with the reduced FPG ob-
served in G6pc2 knockout mice (4) in that the rs573225-A
allele is associated with elevated FPG (Table 1) but
reduced G6PC2 promoter activity. As such, in contrast
with the functional data obtained with rs13431652, these
functional data do not support a potential role for rs573225
as a causative SNP linking G6PC2 to variations in FPG.
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FIG. 5. Comparison of the afﬁnity of Foxa binding to the rs573225-A
and rs573225-G variants of the G6PC2 Foxa binding site in vitro. A: The
labeled rs573225-A oligonucleotide (Fig. 4A) was incubated in the
absence or presence of the indicated molar excess of the unlabeled
human rs573225-A or rs573225-G oligonucleotide competitors (Fig.
4A) before the addition of TC-3 cell or rat liver nuclear extract.
Protein binding was then analyzed using the gel retardation assay as
described in RESEARCH DESIGN AND METHODS. In the representative
autoradiograph shown, only the retarded complexes are visible and not
the free probe, which was present in excess. With TC-3 nuclear
extract, complex A2 represents Foxa2 binding, and complex NS repre-
sents nonspeciﬁc binding (23). With liver nuclear extract, complex A2
represents Foxa2 binding (37). B: Protein binding in experiments
using liver nuclear extract was quantiﬁed by using a Packard Instant
Imager to count
32P associated with the retarded complex. The data
represents the mean  SEM of three experiments. C: The labeled
rs573225-A and rs573225-G oligonucleotides (Fig. 4A) were incubated
with either liver or H4IIE nuclear extract, and protein binding was
analyzed using the gel retardation assay as described in RESEARCH
DESIGN AND METHODS. In the representative audioradiograph shown,
only the retarded complexes are visible and not the free probe, which
was present in excess. NS, nonspeciﬁc.
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FIG. 6. The human G6PC2 rs573225-G allele is associated with in-
creased G6PC2 promoter activity relative to the rs573225-A allele.
TC-3 cells were transiently cotransfected, as described in RESEARCH
DESIGN AND METHODS, using a lipofectamine solution containing various
G6PC2-luciferase fusion genes in the pGL3 MOD vector (2 g) and an
expression vector encoding Renilla luciferase (0.5 g). The G6PC2-
luciferase fusion genes represented the rs573225-A or -G alleles
present in the context of the human G6PC2 promoter sequence located
between 324 and 3. After transfection, cells were incubated for
18–20 h in serum-containing medium. The cells were then harvested,
and ﬁreﬂy and Renilla luciferase activity was assayed as described in
RESEARCH DESIGN AND METHODS. Results are presented as the ratio of
ﬁreﬂy:Renilla luciferase activity, expressed as a percentage relative to
the value obtained with the rs573225-A allele, and represent the mean
of three experiments  SEM, each using an independent preparation of
each fusion gene plasmid, assayed in triplicate. *P < 0.05 vs.
rs573225-A allele.
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FIG. 7. Interaction between the G6PC2 rs13431652-G and rs573225-G
alleles on G6PC2 promoter activity. TC-3 cells were transiently
cotransfected, as described in RESEARCH DESIGN AND METHODS, using a
lipofectamine solution containing various G6PC2-luciferase fusion
genes in the pGL4 MOD vector (2 g) and an expression vector
encoding Renilla luciferase (0.5 g). The G6PC2-luciferase fusion
genes represented the rs573225-A or rs573225-G alleles and
rs13431652-A or rs13431652-G alleles present in the context of the
human G6PC2 promoter sequence located between 8,563 and 11. After
transfection, cells were incubated for 18 to 20 h in serum-containing
medium. The cells were then harvested, and ﬁreﬂy and Renilla luciferase
activity was assayed as described in RESEARCH DESIGN AND METHODS. Results
are presented as the ratio of ﬁreﬂy:Renilla luciferase activity, expressed
as a percentage relative to the value obtained with the rs573225-A and
rs13431652-A alleles, and represent the mean of eight experiments 
SEM, each using an independent preparation of each fusion gene plasmid,
assayed in triplicate. *P < 0.05 vs. rs573225-A and rs13431652-A alleles.
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ﬂect the combined effects of multiple SNPs, we investi-
gated the interaction between rs573225 and rs13431652 on
G6PC2 fusion gene expression (Fig. 7). The results show a
trend toward the rs13431652-G allele blunting the elevated
expression conferred by the rs573225-G allele, although,
because of the relatively small effects involved and the
inherent variability in transient transfections, the decrease
did not reach statistical signiﬁcance.
DISCUSSION
Genome-wide association studies have recently provided
important new insights about the genetics of common
forms of type 2 diabetes and its related quantitative traits,
especially for FPG (9,12,38). After this ﬁrst discovery
phase, attention is now beginning to focus on the study of
the functional properties of the variants at the conﬁrmed
loci. In this study using a combination of genetic and
functional data, we provide further genetic support for the
primary contribution of G6PC2 to variations in FPG, a
conclusion supported by other genetic studies (13,39–41).
Furthermore, we speciﬁcally demonstrate that 1) the ‘A’
allele of the common variant rs13431652 is strongly asso-
ciated with elevated FPG; 2) the rs13431652-A allele
enhances NF-Y binding to the G6PC2 promoter (Figs. 1
and 2); and 3) the rs13431652-A allele increases fusion
gene expression (Fig. 3). Although we failed to observe
any signiﬁcant correlation between endogenous G6PC2
gene expression and rs13431652 genotypes, probably be-
cause of the limited sample analyzed (N  24), our in situ
data are consistent with the reduced FPG observed in
G6pc2 knockout mice (4) and the hypothesis that G6PC2
would oppose the action of glucokinase, leading to ele-
vated FPG. These data suggest that rs13431652 is a strong
candidate to be a causative SNP that contributes to the
association signal between G6PC2 and FPG, though it is
important to note that our genetic data do not rule out a
signiﬁcant contribution of the intronic variant rs560887.
Future studies will be designed to address our hypothesis
that rs560887 affects G6PC2 mRNA splicing (9).
Our study does not give support to the contribution of
intronic variant rs853789 located in the 19th intron of
ABCB11 to the association signal with FPG in our
European cohorts. In a recent study conducted in Asian
populations, a haplotype tagging variant rs3755157 lo-
cated in the 21st intron of ABCB11 was identiﬁed as
associated with FPG independently from rs560887,
which may support the existence of two independent
signals at this locus (42). In this study, limited attention
was given to the striking differences in allele frequen-
cies between Asians and Europeans, both at rs560887
(MAFEU  0.30 vs. MAFAs  0.03) and rs3755157 (0.12
calculated in our French population and 0.09 in HapMap
CEU population vs. MAFAs  0.38). We believe that
these differences may alter the efﬁciency of these two
SNPs to tag putative causal variant(s), as reﬂected by
the difference in the strength of the associations of
these SNPs observed in Europeans versus Asians. None-
theless, we acknowledge that a more extensive ﬁne
mapping analysis involving a larger number of variants
in this locus will be required to elucidate the contribu-
tion of G6PC2 and ABCB11 variants to the association
signal and provide a more comprehensive genetic as-
sessment of this important locus in the genetic determi-
nation of FPG.
Using a combination of genetic and functional data, we
show that rs573225-A allele is highly associated with
elevated FPG (Table 1), enhanced Foxa2 binding (Figs. 4
and 5), but lower fusion gene expression (Fig. 6), a
correlation that is inconsistent with the reduced FPG
observed in G6pc2 knockout mice (4). As such, unlike the
functional data obtained with rs13431652, these functional
data do not support a potential role for rs573225 as a
causative SNP linking G6PC2 to variations in FPG. In
contrast, Dos Santos et al. (43) recently concluded that
rs573225 is the causative SNP that explains the association
signal between FPG and G6PC2. As in our study, they
observed that the rs573225-A allele is associated with
elevated FPG but lower fusion gene expression, but they
did not comment on the fact that these data are inconsis-
tent with the function of G6PC2. Dos Santos et al. (43) also
suggested that rs573225 is an epiSNP, because the
rs573225-G allele is located at a GpC dinucleotide within
the Foxa2 binding site and methylation of the ‘C’ nucleo-
tide affected Foxa2 binding. However, in contrast with the
well-studied methylation of CpG dinucleotides (44), we
can ﬁnd no reports of the existence of methylated GpC
dinucleotides in mammals, although this modiﬁcation
does exist in ﬁsh (45). Finally, although our fusion gene
data match that of Dos Santos et al. (43), our gel retarda-
tion results are the complete opposite. Dos Santos et al.
(43) report that the rs573225-G allele binds Foxa2,
whereas the rs573225-A allele completely abolishes Foxa2
binding. Their binding data therefore appear to correlate
with their fusion gene data since the rs573225-G allele
confers higher promoter activity. However, a detailed
previous study by Overdier et al. (46) showed that both ‘G’
and ‘A’ nucleotides at this location within the Foxa2
binding site support Foxa2 binding. Our demonstration
that Foxa2 binds with the same afﬁnity to both alleles (Fig.
5A and B), though with different kinetics (Fig. 5C), is
therefore consistent with the observations of Overdier et
al. (46), but not with those of Dos Santos et al. (43).
Moreover, given the importance of Foxa2 for G6PC2
fusion gene expression (supplementary Fig. 4), if the
rs573225-A allele were to abolish Foxa2 binding, Dos
Santos et al. (43) should have detected a major difference
in the level of reporter gene expression conferred by the
promoters containing the rs573225-A and rs573225-G al-
leles instead of the 15% difference reported.
Although the available functional data does not support
a role for rs573225 as a causative SNP, a caveat with the
experiments reported here is that the functional effect of
rs573225 on endogenous G6PC2 gene transcription in vivo
may not be replicated by analyses involving the transient
transfection of fusion genes in islet-derived cell lines.
Thus, fusion gene experiments have several limitations,
including: 1) the absence of chromatin structure in tran-
sient transfection assays (47); 2) the use of a truncated
fusion gene that lacks the ﬁve known G6PC2 transcrip-
tional enhancers (48); and 3) the use of tissue culture cell
lines in which the gene expression proﬁles do not match
that of islets in vivo. All of these factors have the potential
to alter the affect of rs573225 on G6PC2 gene transcrip-
tion. Finally, Foxa2 is known to act as a pioneer factor,
opening chromatin to allow access of other transcription
factors (49). As such, rs573225 may have different effects
on G6PC2 gene expression early in development than in
adults.
In summary, our study provides genetic and functional
evidence supporting an important role for the promoter
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contributes to the association signal between G6PC2 and
FPG, but the data do not preclude a signiﬁcant contribu-
tion of the intronic variant rs560887 or other additional
unidentiﬁed variants.
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